Introduction
LY 121019, now known as cilofungin, is a new antifungal agent which has been shown to be effective against several Candida species, especially Candida afbicans and C. tropicalis, the major causes of disseminated candidosis (2-4,7,8). It has been suggested that thedrugmaybeeffective against C. krusei and C. gfabrata although the minimum inhibitory concentration (MIC) is generally higher for these organisms (2, 7) . Against other Candida strains and other yeast-like fungi cilofungin does not appear to be as active (2) .
Currently, the drug of choice for serious Candida infections is amphotericin B, despite its serious toxicity (6) . In some instances, flucytosine can be added to synergistically treat Candidainfections (5) . Combination therapy with flucytosine and amphotericin B and Flucytosinehas the added advantage of allowing reduction of the daily amphotericin B and Flucytosinedose and thus decreasing the toxicity (1) . We tested cilofungin with amphotericin B and Flucytosineand with flucytosine in vitro to determine if synergism might occur when this new anti-Candida drug was combined with the drugs used commonly in the treatment of candidosis.
Materials and Methods

Fungi
Fifty clinical isolates of Candida species maintained in our laboratory were examined. Organisms grown overnight on Sabouraud dextrose agar (Difco, Inc., Detroit, MT) were suspended in 0.9 '/o saline to a concentration of 2 x lo7 CFU/ml, (0.55 optical density reading at 660 nm). The final inoculum was prepared in either Sabouraud dextrose broth (Difco, Inc.), or yeast nitrogen base broth W B ) (Difco, Inc.), depending on which drug was to be studied. The concentration of cilofungm ranged from 0.04 pg/ml to 40 pg/ml, while that of amphotericin B and flucytosine ranged from 0.01 pg/ml to 10 bg/ml. Each different fungal isolate was added to the 12 wells in a given row so that the final inoculum was 1 x lo3 CFU/well.
Plates were incubated for 24 h at 30°C. The MIC was determined as the lowest concentration showing no visible turbidity using a microtiter plate reader. After determining the MIC for each drug for each of the 50 organisms, synergy studies were performed in a similar manner by determining the MIC for each drug in the presence of a constant amount of the other drug added at a concentration four-fold less than the previously determined MIC. The MIC was read in the same manner as described above. 
After reading the MIC for each isolate, compared with the value for each drug 100 yl was ta&n from those wells which showed to turbidity and plated on Sabouraud dextrose agar for assays involving amphotericin B and Flucytosineand on YNB agar for those involving flucytosine. The plates were incubated at 30°C for 24 hrs and the minimum fungicidal concentration (MFC) was read as thelowest concentration of drug in which only one or no fungal colonies persisted.
Synergy was defined as a four-fold or greater reduction in the MIC or the MFC for the combination as compared with thevalue for each drug alone. Antagonism was defined as a four-fold or greater increase in the MIC or MFC for the combination as alonk. Table 1 shows MICs for cilofungin alone and when combined with either amphotericin B and Flucytosineor flucytosine. In no case was the addition of amphotericin B and Flucytosineto cilofungin synergistic; in only one isolate (C. tropicalis) did the addition of flucytosine to cilofungin produce synergistic inhibition of growth.
-
Results
Antagonism was also uncommon, occurring only once when flucytosine was added to cilofungin. Table 2 shows MICs for amphotericin a MIC for the combination of flucvtosineand flucytosine when used singliand when combined with cilofungin. Addition of cilofungin to amphotericin B and Flucytosinewas synergistic once (C. glabrata) and antagonistic in 5 strains (2 C. tropicalisisolates, and one each of C. glabrata, C. albicaizs, and C. parapsilosis). When cilofungin was added to flucytosine, synergism occurred only once (C. albicans) and antagonism occurred 8 times (3 C. albicaizs strains, 2 C. glabrata, one each of C. tropicalis, C. guilliermondii, and C. lusitaniae).
In every instance except one, antagonism and synergism were only four-fold higher or lower than the MIC for the single drug. In that one instance, a strain of C. glabrata had cilofungin 8-fold greater than that f6r flucytosine alone. Table 3 shows MFC's for cilofungin alone and when combined with either amphotericin B and Flucytosineor flucytosine. No synergism with cilofungin-amphotericin B and Flucytosinewas noted, and in only 3 instances (C. tropicalis) was synergism seen with the cilofungin-flucytosine combination. Antagonism, on the other hand, was seen more frequently.
The addition of amphotericin B and Flucytosineto cilofungin increased the MFC 2 4-fold in 2 C, tropicalis strains and 3 C. albicans strains. The addition of flucytosine to cilofungin was frequently antagonistic, as * C. krusei(2), C. pseudotropicalis (2). C. guilliermondii (I), C. lusitaniae (1) noted in 7 C. albicans, 1 C. tropicalis, and 1 C. parapsilosis isolates. In the 12 instances of synergism noted when MFCs were compared for single vs. two drugs, 7 were only 4-fold decreases in the MFC. Antagonism, which occurred in 37 of the 200 combinations tested, was at the 4-fold level in 18 of the 37 instances.
Discussion
Cilofungin is a new antifungal agent that has a mechanism of action different from other antifungal agents in that it inhibits synthesis of beta-1,3-glucan leading to cell wall damage (3). It is possible that ci- * C. krusei (2), C. pseudotropicalis (2), C. guillierrnondii (I), C. lusitaniae (1) lofungin might act synergistically with other antifungal agents, especially flucytosine, whch acts, not on the cell wall, but at the level of DNA replication (5) . Although it is possible to get synergistic action with two agents active at the level of the cell wall and cell membrane, such as cilofungin and amphotericin B, it seems less likely that this combination will result in synergism. We found that, indeed, cilofungin added to amphotericin B and Flucytosineshowed only minimal synergistic inhibition or killing of any of the Candida species tested. When the corresponding studies were performed, whch looked at the effect of subinhibitory concentrations of amphotericin B added to cilofungin, synergy did not occur in any strain tested.
We also found that synergistic inhibition or killing of Candidu strains was rarely noted with the combination of cilofungin and flucytosine. In fact, antagonism was quite common with this combination. In no instance did a resistant strain become susceptible to cilofungin or flucytosine when the second drug was added.
The usefulness of cilofungin in Cundida infections is not known at this time. It would appear to be active against C. albicans and C. tropicalis by in vitro tests (2, 3, 7). We could not venfy by our in vitro assays a potential role for combination therapy with amphotericin B-cilofungin or flu-cytosine-cilofungin. However, studies comparing cilofungin alone with combination therapy in experimental Candida infections could possibly show an in vivo synergistic effect not detected by in vitro assays.
